How to Get Praluent (Alirocumab) in West Virginia

Is Praluent available in West Virginia?

Yes. Praluent is an FDA-approved prescription biologic, and West Virginia residents can receive it when a licensed prescriber determines it is appropriate and a pharmacy can process the prescription. The October 2025 FDA prescribing information lists its current indications, doses, administration instructions, and safety information. Those federal indications are broader than any single insurer's payment rules. A valid prescription does not by itself guarantee that a plan will cover the claim.

The label permits adult starting regimens of 75 mg every two weeks or 300 mg every four weeks for hypercholesterolemia, with adjustment to 150 mg every two weeks when the LDL-C response is inadequate. The same FDA label describes different dosing for adults with homozygous familial hypercholesterolemia or heterozygous familial hypercholesterolemia undergoing LDL apheresis. The prescriber, not the pharmacy benefit, chooses the clinically appropriate regimen.

What West Virginia Medicaid actually publishes

West Virginia's Bureau for Medical Services publishes a preferred drug list rather than a permanent promise of coverage. The state's 2026 PDL includes Praluent in the PCSK9 inhibitor section and points to full prior authorization criteria. The state also publishes a current Praluent and Repatha criteria document describing the clinical information reviewers expect.

Because formularies and criteria can change, use the West Virginia Medicaid PDL page for the version in force on the submission date. Do not infer approval from an older article, a different state's policy, or a pharmacy's test quote. The operative evidence is the current plan document plus the claim response attached to the member's coverage.

West Virginia Medicaid's criteria have historically focused on the diagnosis, LDL-C results, and use of other lipid-lowering therapy. A useful submission therefore identifies the condition being treated, includes dated lipid values, lists current therapy, and explains prior therapies with doses, dates, outcomes, and adverse effects. This record also aligns with the clinical evidence base: in ODYSSEY OUTCOMES, alirocumab was studied after acute coronary syndrome in patients receiving high-intensity or maximum-tolerated statin therapy, not as an unsupported substitute for basic evaluation (PubMed PMID 30403574).

The West Virginia access checklist

Use this claim-ready sequence before the prescription is sent:

1. Confirm the benefit. Ask whether Praluent is covered under the pharmacy benefit, which specialty pharmacy is in network, and whether prior authorization or step therapy applies.
2. Collect the clinical record. Bring the newest lipid panel, relevant cardiovascular records, diagnosis documentation, and a complete list of statins, ezetimibe, or other lipid-lowering therapies tried.
3. Record treatment outcomes precisely. "Could not tolerate statins" is weaker than drug name, dose, start and stop dates, symptoms, lab findings when relevant, and what happened after discontinuation or rechallenge.
4. Submit the exact plan form. State Medicaid, a Medicaid managed-care plan, Medicare Part D, and an employer plan may ask different questions.
5. Route the prescription correctly. A plan can approve the medicine yet require dispensing through a named specialty pharmacy.
6. Check the adjudicated price. The amount shown after the pharmacy submits the claim is more useful than a generic website estimate.

This sequence separates three different failure points: medical eligibility, benefit authorization, and pharmacy routing. Treating them as one problem creates repeat calls and incomplete resubmissions.

What to do after a denial

Read the reason code or denial letter before sending the same request again. A denial for missing records calls for a corrected submission. A nonpreferred-product denial may require evidence that the plan's preferred alternative was tried or is unsuitable. A benefit exclusion is different: it may require a formulary exception or appeal rather than another routine prior authorization.

Ask the prescriber's office for a copy of what was submitted. Compare it with the plan's current criteria line by line. If a clinical criterion is disputed, the appeal should connect the patient's record to that criterion and cite the relevant source. The FDA prescribing information supports labeled indications and dosing; the ODYSSEY OUTCOMES publication supports outcome evidence in its enrolled population (PubMed PMID 30403574). Neither source proves that every patient meets a payer's contract terms.

Cost and manufacturer support

There is no single "West Virginia price." The final amount can change with the plan, deductible phase, pharmacy network, quantity, dose, and assistance eligibility. Get three numbers when comparing options: the plan's price at its required pharmacy, the pharmacy's cash price, and any eligible support amount. Do not combine a cash coupon with insurance and call the result an insurance copay.

The manufacturer's Praluent payment FAQ says eligible commercially insured patients may pay as little as $50 per month, subject to program terms and an annual cap. It also states that the copay offer is not valid for prescriptions paid by Medicaid, Medicare, VA, Department of Defense, TRICARE, or similar government programs. Eligibility should be checked at the time of use because support terms can change.

For more general payer context, see Praluent Medicaid coverage and Praluent Blue Cross Blue Shield coverage. These related pages cannot replace the member's own West Virginia plan document.

Filling and storing Praluent

Before shipping, confirm that the pharmacy has the correct delivery address and a way to contact the patient. Praluent normally ships refrigerated. The current FDA label directs storage at 36°F to 46°F in the original carton, protected from light, without freezing or shaking. It may be kept at room temperature up to 77°F in the original carton for 30 days and discarded if not used within that period.

The label also tells patients to allow a refrigerated pen to warm at room temperature for 30 to 40 minutes before use and to rotate injection sites. A pharmacist or prescriber should address damaged packaging, temperature excursions, missed doses, and injection training. Guessing about a warm shipment is not worth the risk.